Trial Profile
Expanded Access for CC-486
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Celgene Corporation
- 16 Sep 2020 Status changed from recruiting to completed.
- 05 Nov 2018 New trial record